Garg Jasmin, Arun Priti, Chavan B S
Department of Psychiatry, Government Medical College and Hospital, Sector 32, Chandigarh, India.
Int J Appl Basic Med Res. 2015 May-Aug;5(2):114-8. doi: 10.4103/2229-516X.157162.
Oppositional defiant disorder (ODD) is frequently comorbid with attention deficit hyperactivity disorder (ADHD) and is associated with substantial functional impairments. Methylphenidate and atomoxetine are well-established drugs for the management of ADHD. Some studies from Western countries have reported these drugs to be effective in the management of ODD comorbid with ADHD. This study aimed to assess if methylphenidate and atomoxetine are efficacious in treating Indian children with ODD comorbid with ADHD.
In this prospective, open-label study, 37 patients of age 6-14 years with a diagnosis of ODD comorbid with ADHD randomly received either methylphenidate (dose 0.2-1 mg/kg/day) or atomoxetine (dose 0.5-1.2 mg/kg/day) for 8 weeks. Improvements in ADHD and ODD symptoms were assessed using Vanderbilt ADHD diagnostic parent rating scale (VADPRS).
At 8 weeks, there were statistically significant improvements in both ADHD and ODD symptoms in both methylphenidate and atomoxetine groups, as per VADPRS. The improvements produced and tolerability was comparable in the two groups. 80% of the patients from methylphenidate group and 64.3% patients from atomoxetine group ceased to fulfill the criteria for the presence of ODD at 8 weeks.
Methylphenidate and atomoxetine are effective in the treatment of ODD comorbid with ADHD in short duration.
对立违抗性障碍(ODD)常与注意力缺陷多动障碍(ADHD)共病,且与严重的功能损害相关。哌甲酯和托莫西汀是治疗ADHD的常用药物。西方国家的一些研究报告称,这些药物对治疗与ADHD共病的ODD有效。本研究旨在评估哌甲酯和托莫西汀对治疗患有与ADHD共病的ODD的印度儿童是否有效。
在这项前瞻性、开放标签研究中,37名年龄在6至14岁、诊断为与ADHD共病的ODD患者被随机给予哌甲酯(剂量0.2 - 1毫克/千克/天)或托莫西汀(剂量0.5 - 1.2毫克/千克/天),为期8周。使用范德比尔特ADHD诊断家长评定量表(VADPRS)评估ADHD和ODD症状的改善情况。
根据VADPRS,在8周时,哌甲酯组和托莫西汀组的ADHD和ODD症状均有统计学上的显著改善。两组产生的改善效果和耐受性相当。哌甲酯组80%的患者和托莫西汀组64.3%的患者在8周时不再符合ODD的诊断标准。
哌甲酯和托莫西汀在短期内对治疗与ADHD共病的ODD有效。